CoChat
Sign Up
Cited by 87Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications

Open access
Jianming, Wu, Ling, Li·2016·The Journal of Biomedical Research
DOI 10.7555/jbr.30.20150131PMC PMC5044708
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) is a prevalent and debilitating neurodegenerative disorder in the elderly. The etiology of AD has not been fully defined and currently there is no cure for this devastating disease. Compelling evidence suggests that the immune system plays a critical role in the pathophysiology of AD. Autoantibodies against a variety of molecules have been associated with AD. The roles of these autoantibodies in AD, however, are not well understood. This review attempts to summarize recent findings on these autoantibodies and explore their potential as diagnostic/prognostic biomarkers for AD, their roles in the pathogenesis of AD, and their implications in the development of effective immunotherapies for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7555/jbr.30.20150131

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Circulating plasmocytes producing anti-Aβ42 antibodies are elevated in AD patients compared to age-matched healthy individuals.

    “circulating plasmocytes producing anti-A β 42 antibodies are elevated in AD patients compared to agematched healthy individuals”

    From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [96]

    The “Autoantibodies against Aβ” section (page unavailable) reports higher levels of total serum Aβ autoantibodies in AD patients than in age-matched controls. It does not report elevated numbers of circulating plasmocytes producing anti-Aβ42 antibodies; antibody levels and antibody-producing cell counts are different measurements. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • B cells respond specifically to toxic Aβ peptides.

    “suggesting that B cells respond specif­ ically to toxic A β peptides [95,96].”

    From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [96]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. [3]Selkoe D Mandelkow E Holtzman D Deciphering Alzheimer disease[J]. Cold Spring Harb Perspect Med, 2012, 2(1): a011460. 22315723 PMC3253026
  2. [4]Elkon KB Silverman GJ Naturally occurring autoantibodies to apoptotic cells[J]. Adv Exp Med Biol, 2012, 750: 14- 26. 22903663
  3. [5]Lutz HU Naturally occurring autoantibodies in mediating clearance of senescent red blood cells[J]. Adv Exp Med Biol, 2012, 750: 76- 90. 22903667
  4. [6]Casali P Schettino EW Structure and function of natural antibodies[J]. Curr Top Microbiol Immunol, 1996, 210: 167- 179. 8565555
  5. [7]Cho JH Feldman M Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies[J]. Nat Med, 2015, 21(7): 730- 738. 26121193 PMC5716342
  6. [8]D’Andrea MR Add Alzheimer’s disease to the list of autoimmune diseases[J]. Med Hypotheses, 2005, 64(3): 458- 463. 15617848
  7. [9]Jack CR Jr. Knopman DS Jagust WJ Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers[J]. Lancet Neurol, 2013, 12(2): 207- 216. 23332364 PMC3622225
  8. [10]Clark LF Kodadek T Advances in blood-based protein biomarkers for Alzheimer’s disease[J]. Alzheimers Res Ther, 2013, 5(3): 18. 23659521 PMC3706757
  9. [12]Koyama A Okereke OI Yang T Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis[J]. Arch Neurol, 2012, 69(7): 824- 831. 22451159 PMC3772635
  10. [13]Toledo JB Vanderstichele H Figurski M Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI[J]. Acta Neuropathol, 2011, 122(4): 401- 413. 21805181 PMC3299300
  11. [14]Gaskin F Finley J Fang Q Human antibodies reactive with beta-amyloid protein in Alzheimer’s disease[J]. J Exp Med, 1993, 177(4): 1181- 1186. 8459212 PMC2190957
  12. [15]Du Y Dodel R Hampel H Reduced levels of amyloid beta-peptide antibody in Alzheimer disease[J]. Neurology, 2001, 57(5): 801- 805. 11552007
  13. [16]Weksler ME Relkin N Turkenich R Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals[J]. Exp Gerontol, 2002, 37(7): 943- 948. 12086704
  14. [17]Song MS Mook-Jung I Lee HJ Serum anti-amyloid-beta antibodies and Alzheimer’s disease in elderly Korean patients[J]. J Int Med Res, 2007, 35(3): 301- 306. 17593857
  15. [18]Brettschneider S Morgenthaler NG Teipel SJ Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiola-beled amyloid beta(1-42) peptide[J]. Biol Psychiatry, 2005, 57(7): 813- 816. 15820240
  16. [19]Moir RD Tseitlin KA Soscia S Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients[J]. J Biol Chem, 2005, 280(17): 17458- 17463. 15728175
  17. [20]Hyman BT Smith C Buldyrev I Autoantibodiesto amyloid-beta and Alzheimer’s disease[J]. Ann Neurol, 2001, 49(6): 808- 810. 11409436
  18. [21]Baril L Nicolas L Croisile B Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer’s disease and control subjects[J]. Neurosci Lett, 2004, 355(3): 226- 230. 14732472
  19. [22]Klaver AC Coffey MP Smith LM ELISA measurement of specific non-antigen-bound antibodies to Abeta1-42 monomer and soluble oligomers in sera from Alzheimer 9s disease, mild cognitively impaired, and non-cognitively impaired subjects[J]. J Neuroinflammation, 2011, 8: 93. 21827691 PMC3162899
  20. [23]Gustaw KA Garrett MR Lee HG Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis[J]. J Neurochem, 2008, 106(3): 1350- 1356. 18485104 PMC2575068
  21. [24]Mruthinti S Buccafusco JJ Hill WD Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides[J]. Neurobiol Aging, 2004, 25(8): 1023- 1032. 15212827
  22. [25]Gruden MA Davidova TB Malisauskas M Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters[J]. J Neuroimmunol, 2007, 186(1-2): 181- 192. 17477976
  23. [26]Gustaw-Rothenberg KA Siedlak SL Bonda DJ Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer’s disease: a population-based study[J]. Exp Gerontol, 2010, 45(1): 47- 52. 19819324 PMC2815174
  24. [27]Li Q Gordon M Cao C Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies[J]. BMC Neuroscience, 2007, 8: 22. 17374155 PMC1845169
  25. [28]Maftei M Thurm F Schnack C Increased levels of antigen-bound beta-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer’s disease patients[J]. PLoS One, 2013, 8(7): e68996. 23874844 PMC3715516
  26. [29]Qu BX Gong Y Moore C Beta-amyloid auto-antibodies are reduced in Alzheimer’s disease[J]. J Neuroimmunol, 2014, 274(1-2): 168- 173. 25022335 PMC4410718
  27. [30]Terryberry JW Thor G Peter JB Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis[J]. Neurobiol Aging, 1998, 19(3): 205- 216. 9661995
  28. [31]Rosenmann H Meiner Z Geylis V Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects[J]. Neurosci Lett, 2006, 410(2): 90- 93. 17095156
  29. [32]Bartos A Fialova L Svarcova J Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament[J]. J Neuroimmunol, 2012, 252(1-2): 100- 105. 22948089
  30. [33]Fialova L Bartos A Svarcova J Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis[J]. PLoS One, 2011, 6(11): e27476. 22140442 PMC3226623
  31. [34]Davydova TV Voskresenskaya NI Fomina VG Induction of autoantibodies to glutamate in patients with Alzheimer’s disease[J]. Bull Exp Biol Med, 2007, 143(2): 182- 183. 17970195
  32. [35]Doss S Wandinger KP Hyman BT High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types[J]. Ann Clin Transl Neurol, 2014, 1(10): 822- 832. 25493273 PMC4241809
  33. [36]Busse S Busse M Brix B Seroprevalence of N-methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients[J]. Eur Arch Psy Clin N, 2014, 264(6): 545- 550. 24604707
  34. [37]Myagkova MA Gavrilova SI Lermontova NN Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer’s disease and senile dementia of the Alzheimer type[J]. Bull Exp Biol Med, 2001, 131(2): 127- 129. 11391392
  35. [38]Steiner J Bogerts B Schroeter ML S100B proteinin neurodegenerative disorders[J]. Clin Chem Lab Med, 2011, 49(3): 409- 424. 21303299
  36. [39]Mecocci P Parnetti L Romano G Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer’s disease and vascular dementia[J]. J Neuroimmunol, 1995, 57(1-2): 165- 170. 7706432
  37. [40]Tanaka J Nakamura K Takeda M Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer’s disease[J]. Acta Neurol Scand, 1989, 80(6): 554- 560. 2618583
  38. [41]Dahlstrom A McRae A Polinsky R Alzheimer’s disease cerebrospinal fluid antibodies display selectivity for microglia. Investigations with cell cultures and human cortical biopsies[J]. Mol Neurobiol, 1994, 9(1-3): 41- 54. 7888106
  39. [42]McRae A Martins RN Fonte J Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process[J]. Exp Gerontol, 2007, 42(4): 355- 363. 17140756
  40. [43]Hartmann T Kuchenbecker J Grimm MO Alzheimer’sdisease: the lipid connection[J]. J Neurochem, 2007, 103 Suppl 1: 159- 170. 17986151
  41. [44]Lim WL Martins IJ Martins RN The involvement oflipids in Alzheimer’s disease[J]. J Genet Genomics, 2014, 41(5): 261- 274. 24894353
  42. [45]Gounopoulos P Merki E Hansen LF Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease[J]. Minerva Cardioangiol, 2007, 55(6): 821- 837. 18091649
  43. [46]Binder CJ Shaw PX Chang MK The role of naturalantibodies in atherogenesis[J]. J Lipid Res, 2005, 46(7): 1353- 1363. 15897601
  44. [47]Kankaanpaa J Turunen SP Moilanen V Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer’s disease[J]. Neurobiol Dis, 2009, 33(3): 467- 472. 19130885
  45. [48]McIntyre JA Chapman J Shavit E Redox-reactive autoantibodies in Alzheimer’s patients’ cerebrospinal fluids: preliminary studies[J]. Autoimmunity, 2007, 40(5): 390- 396. 17612901
  46. [49]McIntyre JA Hamilton RL DeKosky ST Redox-reactive autoantibodies in cerebrospinal fluids[J]. Ann N Y Acad Sci, 2007, 1109: 296- 302. 17785318
  47. [50]McIntyre JA Wagenknecht DR Ramsey CJ Redoxreactive antiphospholipid antibody differences between serum from Alzheimer’s patients and age-matched controls[J]. Autoimmunity, 2009, 42(8): 646- 652. 19886736
  48. [52]Hatzifilippou E Koutsouraki E Banaki T Antibodies against GM1 in demented patients[J]. Am J Alzheimers Dis Other Demen, 2008, 23(3): 274- 279. 18509104 PMC10846108
  49. [53]Hatzifilippou E Koutsouraki E Costa VG Antibodies against gangliosides in patients with dementia[J]. Am J Alzheimers Dis Other Demen, 2014, 29(8): 660- 666. 24838532 PMC10852599
  50. [54]Schott K Wormstall H Dietrich M Autoantibody reactivity in serum of patients with Alzheimer’s disease and other age-related dementias[J]. Psychiatry Res, 1996, 59(3): 251- 254. 8930031
  51. [55]Miura Y Miyaji K Chai YL Autoantibodies to GM1 and GQ1balpha are not biological markers of Alzheimer’s disease[J]. J Alzheimers Dis, 2014, 42(4): 1165- 1169. 25024341
  52. [56]Dinkins MB Dasgupta S Wang G The 5XFAD Mouse Model of Alzheimer’s Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden[J]. J Alzheimers Dis, 2015. PMC4593501 25720409
  53. [59]Mielke MM Bandaru VV Haughey NJ Serum ceramides increase the risk of Alzheimer disease: the Women’s Health and Aging Study II[J]. Neurology, 2012, 79(7): 633- 641. 22815558 PMC3414665
  54. [60]Delunardo F Margutti P Pontecorvo S Screening of a microvascular endothelial cDNA library identifies rabaptin 5 as a novel autoantigen in Alzheimer’s disease[J]. J Neuroimmunol, 2007, 192(1-2): 105- 112. 17961730
  55. [61]Deane R Du Yan S Submamaryan RK RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain[J]. Nat Med, 2003, 9(7): 907- 913. 12808450
  56. [62]Mruthinti S Schade RF Harrell DU Autoimmunity in Alzheimer’s disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes[J]. Curr Alzheimer Res, 2006, 3(3): 229- 235. 16842100
  57. [63]Wilson JS Mruthinti S Buccafusco JJ Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance[J]. J Gerontol A Biol Sci Med Sci, 2009, 64(2): 264- 271. 19196906 PMC2655015
  58. [64]Mitchell MB Buccafusco JJ Schade RF RAGE and Abeta immunoglobulins: relation to Alzheimer’s disease-related cognitive function[J]. J Int Neuropsychol Soc, 2010, 16(4): 672- 678. 20441687
  59. [65]Giil LM Kristoffersen EK Vedeler CA Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease[J]. J Alzheimers Dis, 2015, 47(2): 523- 529. 26401573
  60. [66]Mor F Izak M Cohen IR Identification of aldolase as atarget antigen in Alzheimer’s disease[J]. J Immunol, 2005, 175(5): 3439- 3445. 16116239
  61. [67]Vacirca D Delunardo F Matarrese P Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer’s disease[J]. Neurobiol Aging, 2012, 33(4): 753- 766. 20594618
  62. [68]Nagele E Han M Demarshall C Diagnosis of Alzheimer’s disease based on disease-specific auto-atibody profiles in human sera[J]. PLoS One, 2011, 6(8): e23112. 21826230 PMC3149629
  63. [69]Nagele EP Han M Acharya NK Natural IgG auto-antibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease[J]. PLoS One, 2013, 8(4): e60726. 23589757 PMC3617628
  64. [70]Restrepo L Stafford P Magee DM Application of immunosignatures to the assessment of Alzheimer’s disease[J]. Ann Neurol, 2011, 70(2): 286- 295. 21823156
  65. [71]Restrepo L Stafford P Johnston SA Feasibility of an early Alzheimer’s disease immunosignature diagnostic test[J]. J Neuroimmunol, 2013, 254(1-2): 154- 160. 23084373
  66. [72]Reddy MM Wilson R Wilson J Identification of candidate IgG biomarkers for Alzheimer’s disease via combinatorial library screening[J]. Cell, 2011, 144(1): 132- 142. 21215375 PMC3066439
  67. [73]Gold M Pul R Bach JP Pathogenic and physiological autoantibodies in the central nervous system[J]. Immunol Rev, 2012, 248(1): 68- 86. 22725955
  68. [74]D’Andrea MR Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease[J]. Brain Res, 2003, 982(1): 19- 30. 12915236
  69. [75]D’Andrea MR Evidence that immunoglobulin-positive neurons in Alzheimer’s disease are dying via the classical antibody-dependent complement pathway[J]. Am J Alzheimers Dis Other Demen, 2005, 20(3): 144- 150. 16003929 PMC10833268
  70. [76]Bouras C Riederer BM Kovari E Humoral immunity in brain aging and Alzheimer’s disease[J]. Brain Res Brain Res Rev, 2005, 48(3): 477- 487. 15914253
  71. [77]Levin EC Acharya NK Han M Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown[J]. Brain Res, 2010, 1345: 221- 232. 20546711
  72. [78]Nagele RG Clifford PM Siu G Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1-42) deposition[J]. J Alzheimers Dis, 2011, 25(4): 605- 622. 21483091
  73. [79]Acharya NK Nagele EP Han M Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease[J]. J Autoimmun, 2012, 38(4): 369- 380. 22560840
  74. [80]Marchese M Cowan D Head E Autoimmune manifestations in the 3xTg-AD model of Alzheimer’s disease[J]. J Alzheimers Dis, 2014, 39(1): 191- 210. 24150111 PMC4376359
  75. [81]Berry A Vacirca D Capoccia S Anti-ATP synthase autoantibodies induce neuronal death by apoptosis and impair cognitive performance in C57BL/6J mice[J]. J Alzheimers Dis, 2013, 33(2): 317- 321. 22954670
  76. [82]Kellner A Matschke J Bernreuther C Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden[J]. Ann Neurol, 2009, 65(1): 24- 31. 19194878
  77. [84]Dodel R Balakrishnan K Keyvani K Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease[J]. J Neurosci, 2011, 31(15): 5847- 5854. 21490226 PMC6622820
  78. [85]Bach JP Dodel R Naturally occurring autoantibodies against beta-Amyloid[J]. Adv Exp Med Biol, 2012, 750: 91- 99. 22903668
  79. [87]Rinne JO Brooks DJ Rossor MN 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study[J]. Lancet Neurol, 2010, 9(4): 363- 372. 20189881
  80. [88]Sperling RA Jack CR Jr. Black SE Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup[J]. Alzheimers Dement, 2011, 7(4): 367- 385. 21784348 PMC3693547
  81. [89]Piazza F Greenberg SM Savoiardo M Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies[J]. Ann Neurol, 2013, 73(4): 449- 458. 23625526
  82. [90]Boncoraglio GB Piazza F Savoiardo M Prodromal Alzheimer’s disease presenting as cerebral amyloid angi-opathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Abeta autoantibodies[J]. J Alzheimers Dis, 2015, 45(2): 363- 367. 25537009
  83. [91]Morgan D Immunotherapy for Alzheimer’s disease[J]. J Intern Med, 2011, 269(1): 54- 63. 21158978 PMC3074967
  84. [92]Lemere CA Immunotherapy for Alzheimer’s disease: hoops and hurdles[J]. Mol Neurodegener, 2013, 8: 36. 24148220 PMC4015631
  85. [94]Pedersen JT Sigurdsson EM Tau immunotherapy for Alzheimer’s disease[J]. Trends Mol Med, 2015, 21(6): 394- 402. 25846560
  86. [95]Szabo P Relkin N Weksler ME Natural human antibodies to amyloid beta peptide[J]. Autoimmun Rev, 2008, 7(6): 415- 420. 18558354
  87. [96]Relkin NR Szabo P Adamiak B 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease[J]. Neurobiol Aging, 2009, 30(11): 1728- 1736. 18294736
  88. [97]Dodel RC Du Y Depboylu C Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease[J]. J Neurol Neurosurg Psychiatry, 2004, 75(10): 1472- 1474. 15377700 PMC1738770
  89. [98]Du Y Wei X Dodel R Human anti-beta-amy-loid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity[J]. Brain, 2003, 126(Pt 9): 1935- 1939. 12821522
  90. [99]Taguchi H Planque S Nishiyama Y Autoantibody-catalyzed hydrolysis of amyloid beta peptide[J]. J Biol Chem, 2008, 283(8): 4714- 4722. 18086674
  91. [100]Paul S Planque S Nishiyama Y Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide[J]. J Clin Immunol, 2010, 30(Suppl 1): S43- 49. 20454852 PMC3147076
  92. [101]Planque SA Nishiyama Y Sonoda S Specific amyloid beta clearance by a catalytic antibody construct[J]. J Biol Chem, 2015, 290(16): 10229- 10241. 25724648 PMC4400338
  93. [102]Kou J Yang J Lim JE Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer’s disease: prophylactic and therapeutic applications[J]. Mol Neurobiol, 2015, 51(1): 43- 56. 24733587 PMC4198531
  94. [103]Ratner M Biogen’s early Alzheimer’s data raise hopes, some eyebrows[J]. Nature biotechnology, 2015, 33(5): 438. 25965736 Asuni AA Boutajangout A Quartermain D Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements[J]. J Neurosci, 2007, 27(34): 9115- 9129. 17715348 PMC6672191
  95. [105]Yanamandra K Kfoury N Jiang H Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo[J]. Neuron, 2013, 80(2): 402- 414. 24075978 PMC3924573
  96. [106]Castillo-Carranza DL Guerrero-Munoz MJ Sengupta U Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer’s disease mouse model[J]. J Neurosci, 2015, 35(12): 4857- 4868. 25810517 PMC6705372
  97. [107]Mably AJ Kanmert D Mc Donald JM Tau immunization: a cautionary tale?[J]. Neurobiol Aging, 2015, 36(3): 1316- 1332. 25619661

Cited by

Sorted by citations

Authors
Jianming, W., & Ling, L.
Venue
The Journal of Biomedical Research
Publisher
Journal of Biomedical Research
Published
2016
Volume
30
Issue
5
Pages
361
ISSN
1674-8301 (ISSN-L)
DOI
10.7555/jbr.30.20150131
PMC
PMC5044708
OpenAlex
W2501502116
Cited by
87
References
9
Citations by year
2026: 5 · 2025: 8 · 2024: 4 · 2023: 13 · 2022: 12 · 2021: 8 · 2020: 13 · 2019: 13 · 2018: 10 · 2017: 1
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Biomedical Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Minnesota
  • National Heart, Lung, and Blood Institute (R21HL117652)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, autoantibodies, biomarkers, diagnostic biomarkers, prognostic factors, autoimmunity, neuroinflammation, immunotherapy, pathogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review